GMR Solutions Inc.
No SEC Form 4 filings for $GMRS in the last 30 days.
See all $GMRS insider activity →GMR Solutions Inc. (GMRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 gmrs-20260812xex99d1.htm EX-99.1 Exhibit 99.1 GMR Solutions Inc. Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Reaffirms Full Year 2026 Guidance LEWISVILLE, Texas (August 12, 2026) — GMR Solutions Inc. (“GMR” or the “Company”) (NYSE:
GMR Solutions Inc. (GMRS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001898718 0001898718 2026-07-01 2026-07-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Repor
Biotech stocks rose on varied catalysts. Parabilis (PBLS) debuted on Nasdaq, up 58% to $31.60 after pricing a $20.00 IPO of 33.5M shares for ~$670M gross proceeds. Clover Health (CLOV) gained 14% to $4.89 after a court ruling upgraded its 2026 PPO Star Rating to 4.5 from 3.5. Myomo (MYO) rose 17% to $1.54; Shoulder Innovations (SI) up 17% to $17.89; GMRS up 13% to $13.18.
Over the past 7 days, alphai's AI scored 1 news story mentioning GMRS (GMR Solutions Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent GMRS coverage spans earnings, corporate actions and market movers.
Reaffirmed 2026 guidance alongside weaker profitability metrics suggests investors will focus on margin trajectory and cash/leverage progress.
Board refresh and equity grants are unlikely to change near-term fundamentals, but can affect governance expectations and sentiment.
Fresh IPO-era financials and full-year revenue range can drive re-rating if investors treat it as a credible post-IPO operating baseline.
Earnings call provides fresh guidance (2026 revenue $5.89B–$6.18B; high-single-digit adj. EBITDA growth) and a quantified CMS rule-change headwind (<$5M annual).
alphai scores every news story that mentions GMRS with an AI model for sentiment and relevance, and aggregates insider trades from GMR Solutions Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
GMR Solutions Inc. (GMRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 gmrs-20260812xex99d1.htm EX-99.1 Exhibit 99.1 GMR Solutions Inc. Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Reaffirms Full Year 2026 Guidance LEWISVILLE, Texas (August 12, 2026) — GMR Solutions Inc. (“GMR” or the “Company”) (NYSE:
6 min readGMR Solutions Inc. (GMRS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001898718 0001898718 2026-07-01 2026-07-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Repor
2 min readBiotech stocks rose on varied catalysts. Parabilis (PBLS) debuted on Nasdaq, up 58% to $31.60 after pricing a $20.00 IPO of 33.5M shares for ~$670M gross proceeds. Clover Health (CLOV) gained 14% to $4.89 after a court ruling upgraded its 2026 PPO Star Rating to 4.5 from 3.5. Myomo (MYO) rose 17% to $1.54; Shoulder Innovations (SI) up 17% to $17.89; GMRS up 13% to $13.18.
7 min readGMR Solutions (NYSE:GMRS) reported Q1 2026 revenue of $1.46 billion (+6.6% YoY) and adjusted EBITDA of $305 million (+9.7%). The company said its recent IPO leaves net leverage around 3.5x. It cited a 47% rise in 911 nurse navigation calls and nearly $47 million in incremental annualized revenue from new agreements. 2026 guidance targets $5.89–$6.18 billion revenue and high single-digit adjusted EBITDA growth.
12 min read
